Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy
NCT ID: NCT06901206
Last Updated: 2025-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2025-03-31
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
When a baby's oxygen requirement goes up, does NPLUS help to target interventions and reduce oxygen requirements?
Researchers will compare NPLUS to standard treatment.
Participants will:
Have a lung ultrasound performed whenever their oxygen requirement increases by more than 10%.
The ultrasound findings will be used to target interventions that aim to improve air entry in the lungs.
Each time this happens, the researchers will note what happens to the oxygen requirement afterwards.
Each participant will participate for five days. For the first two days, they will be randomized to either the NPLUS arm or the usual care arm.
There is then a 24 hour period of usual care. For the final two days, participants cross over to the other arm of the trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neonatologist-performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy to Prevent Extubation Failure
NCT06469580
Neonatologist-performed Lung Ultrasound in the Delivery Room
NCT06408480
MINImising Total Radiation EXposure in Preterm Infants
NCT06975189
Evaluation of Nasal Non Invasive Ventilation in Management of Neonates With Respiratory Distress Using Lung Ultrasound
NCT06550219
NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS)
NCT03099694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Lung consolidations can be sonographically detected by an absence of the pleural line and therefore the lung sliding and areas with loss of aeration visible as lung with tissue like density. Consolidations can be caused by several conditions (e.g., atelectasis, pneumonia, contusion) and the differentiation can be done by ultrasound.
Preterms are prone for recurrent episodes of loss of aeration due to small airway size and muscular weakness. Lung ultrasound has established in the last years and has become an emerging tool for bedside evaluation and to dynamically assess the lungs in several respiratory conditions. Detecting loss of aeration via lung ultrasound is fast and feasible. Trials have investigated the role of lung ultrasound to guide surfactant admission and extubation failure.
To our knowledge there is no evidence investigating the feasibility of lung ultrasound to guide respiratory therapy for preterms on non-invasive ventilation. Oxygen exposure is associated with numerous complications in preterms and should be maintained as low as possible. Lung ultrasound could be a promising tool for a faster detection of loss of aeration and due to more targeted intervention with the ultrasound knowledge a faster FiO2 reduction could be achieved.
The main objective of this study is to evaluate, if NPLUS performed according to a standardized protocol (lung ultrasound score, LUS) in preterm neonates with an absolute increase ≥ 10% over their baseline FiO2 on non-invasive ventilation can detect loss of aeration resulting in more effective reduction of FiO2 demand through targeted interventions (e.g., temporary PEEP increase for alveolar recruitment, positioning of the patient) compared to routine care.
The present study is a cross-over study evaluating the use of NPLUS to guide respiratory therapy of preterm infants on non-invasive ventilation. After inclusion of the study patient, an observation time of two 48-hour blocks and a washout phase of 24 hours between these two blocks is set. Each 48-hour block is managed according to the assigned treatment (NPLUS or standard care). In the 24-hour washout phase no study-related interventions are performed. The treatment assignments are swapped after the washout phase and in the next 48 hours infants previously assigned to NPLUS receive standard care and infants previously assigned to standard care receive NPLUS. Within these set time periods, each episode of increased persisting (\>10 min) FiO2 demand (absolute increase ≥ 10% over the FiO2 baseline) on non-invasive ventilation is defined as event (e.g., patient 1, event 1). For each event, T0 is the time point when the absolute increase ≥ 10% over the initial FiO2 baseline was reported to the clinician and an intervention may be initiated, and T1 is the time point 1 h after T0. The clinician in charge is informed about the onset of every single event. In both treatment arms, interventions for every occurring event can be considered by the clinician in charge including targeted repositioning of the patient, temporary PEEP increase for alveolar recruitment, changes in ventilatory settings (e.g. change to Bilevel, NIPPV, NAVA), surfactant therapy, indication for a chest x-ray, and indication for thoracic physiotherapy.) In the 48-hour NPLUS block, lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.
For each subject a baseline FiO2 is established for the control and NPLUS periods. The aim of using NPLUS versus standard care when managing an event is to reduce any increase from the subject's baseline in the resolution FiO2 level associated with the event.
The ratio of the FiO2 at resolution of each event to baseline FiO2 is a continuous measurement which is 1 when the resolution FiO2 equals the subject's baseline value. A ratio of 1.2 means the resolution FiO2 for the event is 20% higher than the subject's baseline FiO2, a ratio \<1 indicates the resolution FiO2 for the event is less than the subject's baseline and so on.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NPLUS
In the NPLUS block, lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration.
Neonatologist performed lung ultrasound
Neonatologist performed lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.
Control
Routine Care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neonatologist performed lung ultrasound
Neonatologist performed lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* expected to stay on NCPAP for the following 5 days at the NICU, Royal Hospital for Women, Randwick, Sydney
* provided written informed consent obtained from parents.
Exclusion Criteria
* Major congenital anomalies.
* \>33+0 weeks
* Less than 1 week of age
* Invasive ventilation
* Bilevel or Multilevel non-invasive ventilation
* Not expected respiratory support via CPAP for the following 5 days.
1 Week
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Royal Hospital For Women
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tim Schindler
Senior Staff Specialist, Royal Hospital for Women; Conjoint Associate Professor, University of New South Wales
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tim Schindler BMedSc MBBS FRACP PhD
Role: PRINCIPAL_INVESTIGATOR
Senior Staff Specialist, Royal Hospital for Women, Conjoint Associate Professor, University of New South Wales
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Newborn Intensive Care Unit, Royal Hospital for Women
Sydney, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024/PID01756
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.